Handelsbanken Fonder AB Decreases Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Handelsbanken Fonder AB lowered its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 19,400 shares of the medical equipment provider’s stock after selling 700 shares during the period. Handelsbanken Fonder AB’s holdings in Lantheus were worth $1,736,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LNTH. Signaturefd LLC lifted its holdings in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares in the last quarter. International Assets Investment Management LLC raised its holdings in shares of Lantheus by 4,324.9% during the 3rd quarter. International Assets Investment Management LLC now owns 66,948 shares of the medical equipment provider’s stock worth $7,348,000 after acquiring an additional 65,435 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Lantheus during the 3rd quarter worth $1,863,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Lantheus during the 3rd quarter worth $849,000. Finally, DekaBank Deutsche Girozentrale raised its holdings in shares of Lantheus by 7.9% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 10,551 shares of the medical equipment provider’s stock worth $1,121,000 after acquiring an additional 768 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several analyst reports. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. JMP Securities reiterated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Trading Up 1.4 %

Shares of NASDAQ:LNTH opened at $80.07 on Wednesday. The business has a 50-day moving average price of $89.77 and a 200 day moving average price of $96.81. The company has a market capitalization of $5.57 billion, a price-to-earnings ratio of 13.32 and a beta of 0.44. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.